Oncology was the largest of Medpace Holdings, Inc.’s 6 reported lines in fiscal 2025, at $747.59M — 30% of $2.53B.
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Oncology | $467.80M | $587.10M | $651.24M | $747.59M | ||||||
| Direct Service Revenue | — | — | — | — | ||||||
| Metabolic | $296.91M | $404.84M | $431.38M | $408.55M | ||||||
| Other | $244.68M | $376.84M | $457.54M | $744.96M | ||||||
| Central Nervous System | $118.03M | $193.69M | $230.45M | $239.37M | ||||||
| Avai | $157.94M | $160.06M | $181.98M | $254.84M | ||||||
| Cardiology | $174.63M | $163.31M | $156.46M | $134.94M | ||||||
| Reimbursed Out Of Pocket Revenue | — | — | — | — | ||||||
| Revenue Net | — | — | — | — | ||||||
| Total | $1.46B | $1.89B | $2.11B | $2.53B |
In fiscal 2025, which ended December 31, 2025, the 6 revenue lines Medpace Holdings, Inc. reported in this breakdown added up to $2.53B. That was up 20.0% from $2.11B in fiscal 2024. Oncology was the largest revenue line, at $747.59M or 29.5% of the total, followed by Other ($744.96M, 29.4%) and Metabolic ($408.55M, 16.1%). Together, the two largest revenue lines made up 59.0% of this total.
Compared with fiscal 2024, Other grew the fastest, rising 62.8% to $744.96M. Cardiology fell the most, down 13.8% to $134.94M. Over fiscal 2022 to 2025, revenue across these revenue lines went from $1.46B to $2.53B, a compound annual growth rate of 20.1%. Oncology's share of the total fell from 32.0% to 29.5% over the same years.
The table also keeps 3 revenue lines that Medpace Holdings, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 3 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2016 to 2025, as reported in Medpace Holdings, Inc.'s annual filings.
Medpace Holdings, Inc. (MEDP) breaks its revenue down by revenue line. In fiscal 2025, its largest revenue line was Oncology, with $747.59M or 29.5% of the total, followed by Other at $744.96M (29.4%).
Oncology was Medpace Holdings, Inc.'s largest revenue line in fiscal 2025, with $747.59M in revenue, 29.5% of the $2.53B reported across its 6 revenue lines.
Of the Medpace Holdings, Inc. revenue lines reported in both fiscal 2024 and fiscal 2025, and making up at least 2% of the total, Other grew the fastest, rising 62.8% from $457.54M to $744.96M.
Every figure is taken from Medpace Holdings, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2016 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.